Clinical Trial Update: An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

An open-label, long-term Phase 3 study evaluating AL-4943A ophthalmic solution, 0.2%, in allergic conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• AL-4943A ophthalmic solution, 0.2%

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED